Sidana A, et al. - Experts compared the prostate cancer yield of magnetic resonance imaging (MRI) fusion biopsy (FBx) to systematic biopsy (SBx) in a multi-institutional cohort comprised of patients with prior negative biopsies. In patients with prior negative systematic biopsy, FBx outperformed SBx. In part, decreasing clinically significant (CS) cancer detection rate (CDR) by SBx with an increased number of prior biopsies led to this. Findings demonstrated a constant yield of FBx and with the increased number of prior negative biopsies, it did not decrease. Hence, lower yield will hinder the repeat SBx alone in patients with multiple prior negative biopsies. In these patients, FBx ought to be utilized concurrently.